Make Room for Naloxone in the Medication Visit

A psychiatric medication visit can include a careful discussion of sleep, anxiety, and side effects while leaving a practical question unanswered: if this person has an opioid overdose, will anyone nearby have the medication and knowledge to respond?

That question belongs on the agenda when opioid exposure is part of the clinical picture. It need not begin with an accusation about misuse. It can begin with the medicines and circumstances already being discussed.

For a psychiatrist reviewing a benzodiazepine prescription alongside an opioid pain medicine, the safety conversation has more than one job. The combination needs assessment. The patient also needs an understandable account of overdose prevention. Completing one task does not complete the other.

FDA's July 2025 safety communication recommends discussing opioid overdose reversal agents with all patients prescribed opioid pain medicines. It names naloxone and nalmefene and emphasizes the added risks of opioids used with benzodiazepines or other central nervous system depressants, including gabapentinoids.

The accompanying labeling changes identify several reasons access is especially important: concurrent use of other CNS depressants, a history of opioid use disorder, a previous overdose, or household members at risk of accidental ingestion or overdose. These are reasons for a conversation about protection. They are not proof of deception or a diagnosis of a substance use disorder.

The same FDA material says that overdose risk factors should not prevent appropriate pain management. It also warns against rapidly reducing or abruptly discontinuing opioid pain medicines in people who may be physically dependent. Identifying risk calls for a considered response, with the treating clinicians involved, rather than an abrupt medication change to make the list look safer.

This article focuses on naloxone access and education. It does not compare reversal products or select one for every patient. FDA notes meaningful differences among agents, including administration, strength, approved age range, and pharmacokinetics; the relevant product labeling still matters.

"Naloxone discussed" can describe a useful conversation. It can also conceal how little has been settled.

Does the person already have it? If so, where is it? If not, which route to obtaining it is realistic? FDA's current consumer information describes both over-the-counter naloxone products and products requiring a prescription. Knowing that an option exists does not tell us whether the person has obtained it. FDA's consumer guidance also lists people prescribed medicines to treat opioid use disorder among those who should carry naloxone.

A clinician can ask about the next practical step without turning the visit into a procurement checklist. Someone who plans to ask a pharmacist has a different next step from someone who has a product at home but has never opened its instructions. A cost or access problem needs to be heard before it can be addressed.

The conversation should also reach the people who might be present during an emergency, when involving them is appropriate. FDA's consumer guidance says family members and caregivers should be taught to recognize an opioid overdose and give naloxone. A medication that no one can find, or that a potential responder does not know how to use, leaves an important part of the plan unfinished.

As an editorial approach to that teaching, asking someone to explain what they would do may reveal questions that "Do you understand?" misses. This is a proposed conversation, not a validated assessment or evidence that a particular counseling script prevents overdose.

FDA describes warning signs such as unresponsiveness and shallow breathing. A suspected opioid overdose requires immediate emergency help: call 911 and give naloxone if it is available, following its instructions, then stay with the person until help arrives. Do not wait to see whether the medicine works before obtaining emergency assistance.

Naloxone's effects are temporary. A person can become unresponsive again, and repeat administration may be needed. Waking up does not end the emergency or make further medical assessment unnecessary.

The opioid-specific limit also deserves clear language. SAMHSA explains that overdose reversal medicines can address the opioid component when other substances are involved, but they do not treat a benzodiazepine or stimulant overdose itself. A mixed exposure is therefore a reason to preserve the emergency response, not to assume that a response to naloxone has resolved everything.

Product instructions and appropriate response training provide details that a short article cannot. The aim in the medication visit is to make sure those details are accessible and understood before they are needed.

Providing naloxone does not answer whether the current prescribing arrangement is appropriate. That assessment remains active, including the benefits of treatment, interacting substances, and the person's circumstances. Nor does an emergency medication replace ongoing treatment of pain or opioid use disorder.

For psychiatric practice, the useful contribution may be modest and concrete: identify an unanswered access question, explain why it matters, arrange the appropriate teaching, or coordinate with the clinician already managing opioid treatment. The point is to move beyond a reassuring entry in the medication list.

Before the visit ends, there is a practical question worth asking: what would have to happen for this person and someone nearby to be prepared?

1. FDA. FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use. Drug Safety Communication, July 31, 2025. Official full PDF reviewed October 19, 2026; relevant passages rechecked October 23, particularly professional advice and the reversal-agent labeling changes on pages 12-14.
2. FDA. Access to Naloxone Can Save a Life During an Opioid Overdose. Content current June 16, 2026; full official page reviewed October 19 and rechecked October 23, 2026. Recognition, access, teaching, and emergency-response limits.
3. SAMHSA. Opioid Overdose Reversal Medications. Updated August 12, 2025; full official page reviewed October 19 and rechecked October 23, 2026. Used for the distinction between opioid reversal and other components of a mixed exposure.

Source note: This commentary applies specified federal safety and education materials to a psychiatric medication conversation. It is not a complete overdose-response protocol, a comparison of reversal products, or a guide to opioid or benzodiazepine tapering.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. Patients should coordinate treatment decisions with their treating clinicians.